PMID- 24343974
OWN - NLM
STAT- MEDLINE
DCOM- 20141007
LR  - 20220409
IS  - 1099-1573 (Electronic)
IS  - 0951-418X (Linking)
VI  - 28
IP  - 7
DP  - 2014 Jul
TI  - FOLFOX 4 combined with herbal medicine for advanced colorectal cancer: a 
      systematic review.
PG  - 976-91
LID - 10.1002/ptr.5092 [doi]
AB  - This systematic review evaluates the clinical evidence for the addition of herbal 
      medicines (HMs) to FOLFOX 4 for advanced colorectal cancer (ACRC) in terms of 
      tumor response rate (tRR), survival, quality of life and reduction in adverse 
      events (AEs). Seven electronic databases were searched for randomized controlled 
      trials (RCTs) of FOLFOX4 combined with HMs compared to FOLFOX4 alone. Outcome 
      data for 13 randomized controlled trials were analysed using Review Manager 5.1. 
      Risk of bias for objective outcomes including tumor response and survival was 
      judged as low. Publication bias was not evident. Meta-analyses found the addition 
      of HMs improved tRR (RR 1.25, 95%CI 1.06-1.47, I(2)  = 0%), one year survival (RR 
      1.51, 95%CI 1.19-1.90, I(2)  = 0%) and quality of life in terms of Karnofsky 
      Performance Status (KPS) gained (RR 1.84, 95%CI 1.54-2.19, I(2)  = 0%); 
      alleviated grade 3 and 4 chemotherapy-related AEs for neutropenia (RR 0.33, 95%CI 
      0.18-0.60, I(2)  = 0%), nausea and vomiting (RR 0.34, 95%CI 0.17-0.67, I(2) 
       = 0%) and neurotoxicity (RR 0.39, 95%CI 0.15-1.00, I(2)  = 0%), compared to 
      FOLFOX4 alone. The most frequently used herbs were Astragalus membranaceus, Panax 
      ginseng, Atractylodes macrocephala, Poria cocos, Coix lachryma-jobi and Sophora 
      flavescens. In experimental studies, each of these herbs has shown actions that 
      could have contributed to improved tumor response.
CI  - Copyright (c) 2013 John Wiley & Sons, Ltd.
FAU - Chen, Menghua
AU  - Chen M
AD  - School of Health Sciences, and Traditional & Complementary Medicine Research 
      Program, Health Innovations Research Institute, RMIT University, Bundoora, VIC, 
      3083, Australia.
FAU - May, Brian H
AU  - May BH
FAU - Zhou, Iris W
AU  - Zhou IW
FAU - Xue, Charlie C L
AU  - Xue CC
FAU - Zhang, Anthony L
AU  - Zhang AL
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20131217
PL  - England
TA  - Phytother Res
JT  - Phytotherapy research : PTR
JID - 8904486
RN  - 0 (Organoplatinum Compounds)
RN  - Q573I9DVLP (Leucovorin)
RN  - U3P01618RT (Fluorouracil)
RN  - Folfox protocol
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
MH  - Colorectal Neoplasms/*drug therapy
MH  - Fluorouracil/adverse effects/therapeutic use
MH  - Humans
MH  - Leucovorin/adverse effects/therapeutic use
MH  - Organoplatinum Compounds/adverse effects/therapeutic use
MH  - *Phytotherapy/adverse effects
MH  - Plants, Medicinal/*chemistry
MH  - Randomized Controlled Trials as Topic
OTO - NOTNLM
OT  - FOLFOX
OT  - colorectal cancer
OT  - herbal medicine
OT  - meta-analysis
OT  - quality of life
OT  - tumor response
EDAT- 2013/12/18 06:00
MHDA- 2014/10/08 06:00
CRDT- 2013/12/18 06:00
PHST- 2013/06/24 00:00 [received]
PHST- 2013/09/06 00:00 [revised]
PHST- 2013/11/07 00:00 [accepted]
PHST- 2013/12/18 06:00 [entrez]
PHST- 2013/12/18 06:00 [pubmed]
PHST- 2014/10/08 06:00 [medline]
AID - 10.1002/ptr.5092 [doi]
PST - ppublish
SO  - Phytother Res. 2014 Jul;28(7):976-91. doi: 10.1002/ptr.5092. Epub 2013 Dec 17.